Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Clinical Outcomes of Bilateral Clareon Vivity in Post-Refractive Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Millions of people have undergone laser vision correction surgery and are motivated to continue with spectacle independence as they develop presbyopia (gradual loss of your eyes' ability to focus on nearby objects)and cataract. However, having a history of refractive surgery, poses challenges in the selection of the IOLs and can lead to visual outcomes that are unpredictable. Data from an international registry and single prospective study show that Vivity IOL provided effective distance, intermediate and near vision in eyes with previous LASIK with minimal effects on day vision associated with the surgery. The purpose of this study is to evaluate the clinical outcomes of post-myopic refractive surgery patients implanted with the Clareon Vivity/Vivity Toric lenses

Who May Be Eligible (Plain English)

Who May Qualify: - o Bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing uncomplicated bilateral sequential Clareon Vivity IOLs - Prior history of uncomplicated post-refractive myopic surgery (LASIK/PRK) with up to 1 enhancement treatment - Potential acuity measured post-operatively 20/25 or better in both eyes - Patients with regular astigmatism that can be managed with T3 toric lens or arcuate incision Who Should NOT Join This Trial: - o Ocular or systemic comorbidities that may alter or reduce visual acuity and contrast sensitivity such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, etc. - Prior ocular surgeries other than uncomplicated corneal refractive surgery and excluding RK - Patients with irregular astigmatism/topography (to rule out signs of potential ectasia), corneal dystrophies, and pupil abnormalities - Total HOA cutoff of ≤0.5, coma ≤0.3 - RLE patients Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * o Bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing uncomplicated bilateral sequential Clareon Vivity IOLs * Prior history of uncomplicated post-refractive myopic surgery (LASIK/PRK) with up to 1 enhancement treatment * Potential acuity measured post-operatively 20/25 or better in both eyes * Patients with regular astigmatism that can be managed with T3 toric lens or arcuate incision Exclusion Criteria: * o Ocular or systemic comorbidities that may alter or reduce visual acuity and contrast sensitivity such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, etc. * Prior ocular surgeries other than uncomplicated corneal refractive surgery and excluding RK * Patients with irregular astigmatism/topography (to rule out signs of potential ectasia), corneal dystrophies, and pupil abnormalities * Total HOA cutoff of ≤0.5, coma ≤0.3 * RLE patients

Treatments Being Tested

PROCEDURE

cataract surgery

cataract surgery treated with bilateral Clareon Vivity toric and non-toric IOL

Locations (1)

Utah Eye Centers
Ogden, Utah, United States